Home > WorldWIDE slide resource

		WorldWIDE slide resource

Incretin Therapies

Key References

Click on the citation to view the abstract of the key reference. Additional reference citations can be viewed on the PowerPoint slides and notes.

Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186-193.

Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.

Nauck MA, Kleine N, Orskov C, Holst JJ, Wilms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.

Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.

The Incretin Therapies presentation is supported by an unrestricted educational grant from Merck & Co., Inc. (Merck Sharp & Dohme).

Return to WorldWIDE homepage